Home › Trials › NCT06046729

Testing eltrekibart for treating moderate to severe hidradenitis suppurativa in adults

A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 2 Interventional Eli Lilly and Company · NCT06046729

This study is testing a new medication called eltrekibart to see if it can help adults with moderate to severe hidradenitis suppurativa feel better.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment350 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorEli Lilly and Company Industry-sponsored
Locations75 sites (Phoenix, Arizona and 74 other locations)
Trial IDNCT06046729 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and effectiveness of eltrekibart in adults diagnosed with moderate to severe hidradenitis suppurativa (HS). Participants will receive either eltrekibart or a placebo over approximately 62 weeks, with up to 31 visits to assess the appropriate dosing and frequency. The study aims to determine the optimal treatment regimen for further clinical development in managing HS.

Who should consider this trial

Good fit: Ideal candidates are adults with a diagnosis of hidradenitis suppurativa for at least 12 months and specific lesion characteristics.

Not a fit: Patients with more than 20 draining fistulae or recent surgical treatment for HS may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the management of hidradenitis suppurativa, leading to better patient outcomes.

How similar studies have performed: While this approach is being explored in this specific context, similar studies have shown promise in treating hidradenitis suppurativa with novel therapies.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Have a diagnosis of HS for at least 12 months.
* Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.
* Have an (abscess plus inflammatory nodule) count of at least 5.
* Agree to use topical antiseptics daily.
* Had an inadequate response or intolerance to a 28-day course of oral antibiotics.

Exclusion Criteria:

* Have more than 20 draining fistulae.
* Have had surgical treatment for HS in the last 4 weeks before randomization.
* Have an active skin disease or condition, that could interfere with the assessment of HS.
* Have a current or recent acute, active infection.
* Are immunocompromised.
* Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.

Where this trial is running

Phoenix, Arizona and 74 other locations

+25 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Hidradenitis Suppurativa
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.